The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > COMMENTARY
COMMENTARY
-
Beyond Risk Management: RMPs Provide Opportunity for Post-Marketing Drug Development and Product Differentiation
May 8, 2013
-
Iressa Cases Signal Risks Hiding in Daily Clinical Practices
April 22, 2013
-
Will Drugs that Fight Cancer Stem Cells Succeed? Domestic Clinical Trial by DSP on the Horizon
March 15, 2013
-
Gov’t, Industry to Support Developing Countries through Development of Drugs for Infectious Diseases; Hoping to Secure Future Business Opportunities as Well
February 27, 2013
-
What Next for a “Mature” ICH? What More Can Be Done Beyond Regulatory Harmonization?
January 22, 2013
-
Hot Products in 2013: New Drugs Likely to Jolt RA Treatment, Anticoagulant Markets
January 8, 2013
-
Counterfeit Drugs: Risks Lurking in Globalization
December 28, 2012
-
Can Japan Craft Its Own “Compassionate Use” System without Spoiling Drug Makers’ Development Drives?
December 7, 2012
-
Recent Announcements of Suspended Product Supplies Highlight Supply Risks Faced by Generic Drug Industry
November 27, 2012
-
Will Integration of Domestic Makers Be Enough for Sustainable Plasma Fractionation Operations?
November 16, 2012
-
Approval of Switch-OTC Epadel Puts Spotlight on Quality, Track Record of Pharmacists
November 9, 2012
-
Final Preparations Underway for Trial Run of Medical Database
September 25, 2012
-
Competition Getting Fiercer in COPD Drug Market
September 13, 2012
-
FY2013 Budget Expected to Have Positive Impact on Pharmaceutical and Medical Device Industries
August 30, 2012
-
Pharmaceutical Bar Coding Initiatives Spreading Among Western Countries
August 21, 2012
-
Government Shows Consideration towards Municipalities on IPV Price Issue
August 14, 2012
-
Challenges Emerging from Hiroshima: Improvement of Wholesalers' “Services of Convenience”
August 1, 2012
-
Integration of Advanced Healthcare System to Strengthen Linkage Between Development, Insurance, and Regulatory Approval
July 10, 2012
-
Major Generic Drug Makers Trying New Strategies to Boost Product Strengths
July 6, 2012
-
Gov’t to Support Development of Innovative Drugs of Japanese Origin through Drug Discovery Support Network
June 22, 2012
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…